1. Scrip
  2. >>Leadership

Agios Recruits Rare Disease Leader Brian Goff As CEO To Execute Commercial Transition

 
• By Jessica Merrill

Leadership change comes after CEO Jackie Fouse, who will serve as board chair, oversaw the sale of Agios' cancer portfolio, a reorganization and a shift in therapeutic focus to rare diseases.

chess piece representing a leader
Agios appointed a new CEO Brian Goff • Source: Shutterstock

The stars aligned for Agios Pharmaceuticals, Inc. to bring former Alexion Pharmaceuticals Inc. commercial head Brian Goff on board as CEO to oversee the launch of the company's first rare disease drug, Pyrukynd (mitapivat), according to CEO Jackie Fouse, who will hand the leadership reins to Goff in August.

Agios announced the leadership transition after market close on 12 July, with Fouse stepping into the role of board chair at a big turning point for the company. In just three years at the helm of Agios, Fouse helped the firm pivot its therapeutic focus, including the sale of the company's cancer portfolio last year to Les Laboratoires Servier for $2bn to concentrate instead on drugs for genetically-defined rare diseases

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

Mission Vision: How Roche Hopes To Impact Eye Health Outcomes In APAC

 
• By Anju Ghangurde

Roche Pharmaceuticals’ area head, Asia Pacific, outlines how the Swiss group is helping nurture the wider ecosystem and setting itself up for a bigger play in the ophthalmology space by combining scientific expertise with regional insights.

How Much Does Biopharma Contribute To The US Economy?

 
• By Jessica Merrill

A new IQVIA report highlights how the sector benefits the US through metrics like the economy, employment and health.

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

More from Scrip

HHS Intensifies Pressure On Pharma With MFN Pricing Benchmark

 
• By Jessica Merrill

The Trump administration released more details on “most favored nation” price targets drug companies are expected to apply to US drug prices.

Asia Deal Watch: Lilly Partners With Rznomics On Hearing Loss

 
• By Joseph Haas, Xu Hu, Anju Ghangurde, and Lisa Takagi

Plus deals involving Minghui/Qilu, LENZ/Lotus, Amicus/Dimerix, Sanofi/Dr. Reddy’s, Henlius/Lotus, Apnimed/Desitin, Formosa/Saval, DAAN/GC Cell, VelaVigo/Ollin and Sol-Gel/Mayne.

Boehringer’s Next Generation IPF Drug Underwhelms

 
• By Andrew McConaghie

The company hoped its follow-up to blockbuster Ofev could clearly improve efficacy and safety benefits, but the full Phase III results from nerandomilast’s FIBRONEER-IPF fall short of a slam dunk.